OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company specializing in antibody discovery platforms that completed its public debut through a de-SPAC merger with Avista Public Acquisition Corp. II, a blank-check vehicle sponsored by Avista Capital Partners that held its IPO in 2021. Spun out of Ligand Pharmaceuticals, OmniAb closed its business combination in October 2022 and operates in the life sciences sector, providing transgenic animal-based antibody discovery technologies to pharmaceutical and biotech partners worldwide. The company filed an 8-K with the SEC on May 7, 2026, under accession number 0001846253-26-000035. Sign up at SpacDesk for full data on OmniAb, its SPAC history, and thousands of other transactions.